SER Stock Forecast: Serina Therapeutics, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Serina Therapeutics, Inc. is $9.5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 18 of 100 as at 21 Nov 2026 — in the weakest quartile.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Serina Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (52): The share price has been relatively steady.
Growth (10): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
SER stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on SER, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 26 Oct 2026 | BTIG | Reiterates | Buy | — |
| 10 Sept 2026 | BTIG | Reiterates | Buy | — |
| 1 July 2026 | BTIG | Initiates | Buy | — |
| 28 Aug 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 14 July 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 11 Mar 2025 | Jones Trading | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for SER.
This page is one stock. Monday covers all of them.
SER appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
SER vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Serina Therapeutics, Inc. returned −70.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
SER analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 238.1×
- Price / book
- 2.1×
- EV / EBITDA
- —
Cheaper than 2% of US stocks
Cheaper than 41% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −315.8%
- Return on assets
- −98.9%
- Dividend yield
- —
Higher than 5% of US stocks
Higher than 3% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Serina Therapeutics, Inc. has a market value of $29.8M and an enterprise value of $13.7M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$21.2M.
Free cash flow in the twelve months to 30 June 2026: −$21.2M.
Serina Therapeutics, Inc. employs 16 people.
Data provided by Twelve Data
SER and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at SER’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Serina Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about SER
What is the SER stock price forecast for 2026-2027?
The median 12-month analyst price target for Serina Therapeutics, Inc. is $9.5, with estimates ranging from $8 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is SER stock a buy right now?
Of the 2 analysts covering Serina Therapeutics, Inc., 2 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Serina Therapeutics, Inc. 18 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank SER?
As at 21 Nov 2026, Serina Therapeutics, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (52 of 100).
Will SER stock go up?
No one can know that. What the data says: the median 12-month target from 2 analysts is $9.5, and Ticker Nerd's factor model ranks Serina Therapeutics, Inc. 18 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the SER stock forecast for 2030?
No analyst covering Serina Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SER are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $11 over the next 12 months.
How has SER stock performed over the past year?
Serina Therapeutics, Inc. returned -70.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Serina Therapeutics, Inc. do?
Serina Therapeutics Inc. is a clinical-stage biotechnology company focused on developing polymer-enabled therapeutics for neurological diseases and other serious conditions. The company’s core work centers on its proprietary POZ Platform, a drug-delivery technology designed to improve how medicines are loaded, released, and administered, with applications across small molecules, RNA-based therapies, and antibody-drug conjugates.
About Serina Therapeutics, Inc.
Serina Therapeutics Inc. is a clinical-stage biotechnology company focused on developing polymer-enabled therapeutics for neurological diseases and other serious conditions. The company’s core work centers on its proprietary POZ Platform, a drug-delivery technology designed to improve how medicines are loaded, released, and administered, with applications across small molecules, RNA-based therapies, and antibody-drug conjugates. Serina Therapeutics Inc. is advancing a pipeline of wholly owned product candidates aimed primarily at central nervous system disorders, including Parkinson’s disease, along with programs in pain and other therapeutic areas. Its current business is centered on research, preclinical development, and clinical evaluation of drug candidates built around its platform technology. Based in Huntsville, Alabama, Serina Therapeutics Inc. plays a specialized role in the biotechnology market by combining materials science with drug development to address treatment challenges in difficult-to-deliver therapies.
CEO Mr. Steven A. Ledger · 16 employees · United States · https://www.serinatx.com